Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies
| Autor: | Erica Mencarelli, Adele D'Amico, Fabrizio Drago, Rachele Adorisio, Massimo Stefano Silvetti, Marianna Cicenia, Maria Grandinetti, Liliana Amato, Antonio Amodeo, Nicoletta Cantarutti, Camilla Calvieri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty congenital hereditary and neonatal diseases and abnormalities Duchenne muscular dystrophy Cardiomyopathy heart failure lcsh:Medicine Review 030204 cardiovascular system & hematology Pharmacological treatment 03 medical and health sciences 0302 clinical medicine Internal medicine medicine cardiovascular diseases Therapeutic strategy duchenne muscular distrophy biology business.industry lcsh:R Dilated cardiomyopathy Angiotensin-converting enzyme General Medicine medicine.disease dilated cardiomyopathy medicine.anatomical_structure Ventricle Heart failure biology.protein Cardiology cardiovascular system business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Clinical Medicine, Vol 9, Iss 3186, p 3186 (2020) Journal of Clinical Medicine |
| ISSN: | 2077-0383 |
| Popis: | Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|